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ABSTRACT
Introduction: Chronic obstructive pulmonary disease
is generally progressive and associated with reduced
physical activity. Both pharmacological therapy and
exercise training can improve exercise capacity;
however, these are often not sufficient to change the
amount of daily physical activity a patient undertakes.
Behaviour-change self-management programmes are
designed to address this, including setting motivational
goals and providing social support. We present and
discuss the necessary methodological considerations
when integrating behaviour-change interventions into a
multicentre study.
Methods and analysis: PHYSACTO is a 12-week
phase IIIb study assessing the effects on exercise capacity
and physical activity of once-daily tiotropium+olodaterol 5/
5 µg with exercise training, tiotropium+olodaterol 5/5 µg
without exercise training, tiotropium 5 µg or placebo, with
all pharmacological interventions administered via the
Respimat inhaler. Patients in all intervention arms receive
a behaviour-change self-management programme to
provide an optimal environment for translating
improvements in exercise capacity into increases in daily
physical activity. To maximise the likelihood of success,
special attention is given in the programme to: (1) the Site
Case Manager, with careful monitoring of programme
delivery; (2) the patient, incorporating patient-evaluation/
programme-evaluation measures to guide the Site Case
Manager in the self-management intervention; and (3)
quality assurance, to help identify and correct any
problems or shortcomings in programme delivery and
ensure the effectiveness of any corrective steps. This
paper documents the comprehensive methods used to
optimise and standardise the behaviour-change self-
management programme used in the study to facilitate
dialogue on the inclusion of this type of programme in
multicentre studies.
Ethics and dissemination: The study has been
approved by the relevant Institutional Review Boards,
Independent Ethics Committee and Competent Authority
according to national and international regulations. The
results of this study will be disseminated through relevant,
peer-reviewed journals and international conference
presentations.
Trial registration number: NCT02085161.
INTRODUCTION
Patients with chronic obstructive pulmonary
disease (COPD), a common and treatable
disease,1 have reduced walking time, standing
time and movement intensity in daily life.2 3
Reduced physical activity has been suggested to
lead to a downward spiral of symptom-induced
inactivity (figure 1),4 which could directly impact
on hospital readmission as well as patient
outcomes, quality of life and mortality.5–7
Recently, the European Respiratory Society
reviewed the evidence for increasing physical
activity as part of an integrated programme
of COPD management, finding a relation-
ship between low levels of physical activity
and magnitude of decline in lung function.8
While both pharmacological therapy and
exercise training can improve exercise cap-
acity,9–12 evidence suggests that supervised
exercise training (ie, pulmonary rehabilita-
tion) without modification of patient
Strengths and limitations of this study
▪ Behaviour-modification interventions performed
by Site Case Managers who have recognised
expertise in chronic obstructive pulmonary
disease.
▪ Site Case Managers received formal training
prior to study initiation and are supported
throughout the study with educational opportun-
ities and performance feedback.
▪ Behavioural intervention is well defined including
new methods for quality assurance.
▪ The main limitation is the design of the trial,
since there is no group that does not receive the
behaviour-change intervention. Inclusion of this
group would allow the impact of the behaviour-
change intervention to be evaluated.
▪ Another limitation is that due to budget con-
straints, there is no long-term follow-up to assess
whether changes in patient behaviour are
sustained.
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behaviour is unlikely to be sufficient to change the actual
amount of daily physical activity that a patient engages in,
regardless of improvements in exercise capacity.13
Behaviour-change interventions, such as evidence-based
self-management training and support, including setting
patient goals, are designed with this in mind14 and may
be more effective when delivered in a structured manner,
specific to the health problem of interest.15 16
Several studies have included behaviour-targeted pro-
grammes with the aim of increasing physical activity in
adults with chronic diseases, including COPD, diabetes,
heart failure and obesity.17 Across these studies, pro-
grammes were performed in conjunction with exercise
training and included education, training, counselling,
behaviour-change support and/or follow-up sessions.17
In studies of coronary heart disease, psychosocial inter-
ventions including cognitive behavioural therapy, stress
management and antidepressant treatment have been
shown to reduce cardiac events, while cardiac rehabilita-
tion, including exercise training, reduced mortality.18
There are many design issues to take into consider-
ation when implementing behavioural interventions in a
study.19 These interventions are complex, involving mul-
tiple inter-related components, and must be standar-
dised but personalised and administered consistently to
all patients to show a treatment effect. Programme varia-
tions, together with the level of care providers’ expertise
(eg, the case manager), can have a profound impact on
treatment outcomes. Published studies provide little
guidance, lacking the necessary details (eg, type, quan-
tity, timing and method of delivery; tools used;
quality-assurance methods) to replicate or inform adap-
tations of the intervention.
This paper presents and discusses new approaches for
the implementation of a behaviour-change self-
management programme into a multicentre study in
COPD, with special attention paid to methodological
issues (intervention design, delivery and surveillance/
quality control). This is illustrated with the PHYSACTO
study, a phase IIIb study designed to assess the effect of
a new COPD maintenance bronchodilator therapy and
supervised exercise training on exercise capacity (primary
outcome as measured by the endurance shuttle walk test)
and physical activity (secondary outcomes including
the amount of physical activity (measured using the
PROactive tool) and perceived difficulties). The inclusion
of the behaviour-change self-management programme in
all intervention arms (including placebo) provides an
optimal environment for translation of improvements in
exercise tolerance into increases in physical activity. The
objectives with respect to the behaviour-modification pro-
gramme are to explore the extent to which potential
moderating variables (eg, motivation, self-efficacy, cogni-
tive function, anxiety and depression, and external and
internal barriers) could influence the increase in physical
activity during everyday tasks. A self-management pro-
gramme such as this, based on complex interactions, is
associated with several specific challenges, which we will
describe, including how to ensure the intervention is
delivered consistently ‘per protocol’ by intervention provi-
ders across this multicentre study.
METHODS
Study design
PHYSACTO is a 12-week, randomised, partially double-
blind, placebo-controlled, multisite, international, four-
parallel group study (NCT02085161) in patients with a
diagnosis of COPD. The purpose of the study is to evalu-
ate the effects on exercise capacity and physical activity of
administration of COPD maintenance pharmacotherapy
alone or in combination with supervised exercise train-
ing. Full inclusion and exclusion criteria are detailed else-
where20 and will not be discussed here. The study is
being conducted in 11 countries at 34 study sites, each
contributing and managing an average of eight patients.
Overall, the PHYSACTO study plans to continue until 300
patients have been randomised.
Interventions and incorporation of a behaviour-change
programme into the study
Following a 4-week washout period, patients are rando-
mised to once-daily tiotropium+olodaterol 5/5 μg com-
bined maintenance treatment with exercise training,
tiotropium+olodaterol 5/5 µg combined maintenance
treatment without exercise training, tiotropium 5 µg or
placebo, with all pharmaceutical treatments adminis-
tered via the Respimat inhaler (Boehringer Ingelheim,
Ingelheim am Rhein, Germany) and a behaviour-change
programme included in all intervention groups.
Study outcomes
The primary aim is to assess the effects on exercise cap-
acity of tiotropium+olodaterol or tiotropium alone or in
conjunction with supervised exercise training. The
Figure 1 Decline in lung function in chronic obstructive
pulmonary disease is associated with inactivity and avoiding
exercise, leading to a spiral of declining patient condition.
Reprinted from The American Journal of Medicine, Vol 119
(10A), Reardon et al.4 Functional status and quality of life in
chronic obstructive pulmonary disease, S32–37, Copyright
2006, with permission from Elsevier.
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secondary aim is to assess the extent to which pharmaco-
therapy and exercise training can enhance the effects of
the behaviour-change programme on the amount and
perceived difficulty of physical activity.
Study outcome measures are described in the compan-
ion paper.20 Briefly, the primary outcome of the study is
endurance time during an endurance shuttle walk test to
symptom limitation after 8 weeks of therapy. Secondary
outcomes include assessments of patients’ levels of phys-
ical activity using an activity monitor,8 patients’ reports of
the ease or difficulty with which they perform daily activ-
ities quantified by the Functional Performance Inventory
—Short Form,21 22 a daily activity diary completed on the
days patients wear the activity monitor, and lung function.
Exploratory end points are included to examine the
extent to which certain patient variables moderate the
relationship between exercise capacity and physical
activity. These patient-reported measures and question-
naires include cognitive function (Montreal Cognitive
Assessment),23 anxiety and depression (Hospital Anxiety
and Depression Scale)24 and the presence of major
depressive disorder (Brief Patient Health Questionnaire-
mood).25 26
The behaviour-change self-management programme
A 12-week behaviour-change programme is included in
all arms of the PHYSACTO study to provide an optimal
environment for translation of improvements in exercise
capacity into long-term increases in daily physical activ-
ity. Most exercise-intervention studies in chronic diseases
published to date have focused on targeting the patient
via educational programmes, counselling or exercise
programmes, in order to achieve changes in daily phys-
ical activity.17 Our approach is designed to effect
changes in patient behaviour by: building on the experi-
ence, training and effectiveness of case managers; stan-
dardising the content of the programme across sites;
helping case managers adjust the programme based on
patient responses using a standardised feedback process;
and including quality-assurance steps throughout the
programme. Because PHYSACTO is a multicentre study,
we have to ensure that delivery of the behaviour-change
self-management programme can be standardised across
different locations, while also ensuring that individual
patient needs, preferences and personal goals inform
the intervention.
The Site Case Manager: selection and training
The Site Case Manager (SCM) is required to have a
minimum of 2 years’ experience working with patients
with COPD and recognised expertise in the area. To
optimise the quality and impact of the behaviour-change
intervention, we provide 3 days of standardised training
to the SCMs in evidence-based behaviour-change techni-
ques (eg, motivational communication, goal setting,
reinforcement and problem solving) that is supplemen-
ted by online tutorials (training reviews, case studies) and
systematic feedback from the behaviour-modification
team if performance is judged to be unsatisfactory. This
training is based on the self-management educational
programme ‘Living Well with COPD’,27 which is
designed to help patients with COPD and their families
cope with their disease on a daily basis, while a reference
guide can assist the healthcare professionals in engaging
with their patients and facilitating improved disease
self-management.
The programme has been adapted for the current
study by focusing on improving patient engagement in,
and maintenance of, exercise and physical activity. An
important element of the educational programme is
training in the principles of behaviour change and
methods to engage, motivate and build patient confi-
dence. Basic training in motivational communication
skills includes using open questions and building motiv-
ation to engage patients in more physical activity, using
reflective listening to manage and overcome resistance,
and providing information by offering, sharing and
asking patients for feedback.28
The educational programme
The educational programme schedule for patients starts
with an individual induction session at the beginning of
the intervention period, followed by group sessions at
weeks 2, 5, 8 and 11, with another individual session at
follow-up (figure 2). The sessions are led by the SCM,
who guides the patient in self-management behaviours
that aid in achieving physical activity goals, while improv-
ing daily COPD management.
Individual induction session: During the individual
induction session, the SCM performs an assessment to
determine the patient’s current level of physical activity,
functional limitations and any clinical barriers to phys-
ical activity (including motivation). The patient is also
given a printed booklet from the ‘Living Well with
COPD’ programme, described further below. The
patient’s ultimate goal is defined at this stage as their
desired achievements in work, home and leisure by the
end of the programme. The SCM coaches the patient to
define and reach their ultimate physical-activity goal (eg,
what they will be able to do at the end of the pro-
gramme, such as being able to play in the park with
their grandchildren). This ensures that the patient
remains engaged and motivated in the pursuit of their
physical activity goals. This is followed by instructions on
the use of the pedometer (including a demonstration
by the patient to test competency), which is subse-
quently used during the study for setting intermediate
goals (eg, number of daily steps before the next
session). The educational materials provided to the
patient specify an example of an objective for patients.
These materials state: “Your first objective will be to add
1000 steps to your daily average. Maintain this level over
a 1-month period. If you reach your goal, add another
1000 steps and maintain this for 1 month. Keep increas-
ing your objective in this way until you have reached
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5000 to 6000 steps per day. If your condition allows it,
you can keep increasing up to 10,000 steps per day.” The
SCM records the patient’s progress throughout the study
using a patient worksheet (see online supplementary
appendix 1). For each session, there is also an itemised
session evaluation that is completed by the SCM (see
online supplementary appendix 2). Patient worksheets,
session-evaluation forms and patient-evaluation/
programme-evaluation questionnaires remain with the
SCM throughout the study in order to track patient
progress.
Group sessions: At the 90–120 min group sessions
(figure 2), the SCM explains the benefits of physical
activity and setting physical-activity goals. Patients select
and review their own personal goals and sign a ‘learning
contract’ as a symbolic gesture to formalise these goals
(group session 2, week 5). Patients also receive
education on their disease, healthy life habits, stress
management, breathing techniques, exercise planning
and how to distinguish normal from abnormal physical
symptoms. In order to respond to the changing needs of
individual patients, the educational programme is
designed to allow for adjustment of the programme
components, as required.
Group sessions are also used to identify any barriers
that may have prevented patients from reaching their
physical-activity goals, with patients regularly reflecting
on their progress and reviewing their goals on paper.
These sessions are supplemented with the ‘Living Well
with COPD’ programme booklet, which contains topics
on promotion of physical activity, COPD and medica-
tion, breathing and energy-conservation techniques,
stress and anxiety management, and improving health
behaviours. Patients are assigned sections to read after
Figure 2 Overview of the behaviour-change programme. COPD, chronic obstructive pulmonary disease.
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each session, and each topic concludes with a series of
questions to test understanding.
Patients’ comprehension, attitudes and skills are
assessed throughout the intervention to determine if
they have met pre-established goals and objectives.
Several methods are used to supplement information
and correct misunderstandings in a constructive way, as
well as reinforce newly acquired skills and behaviours.
These methods include direct open questioning,
problem-solving exercises, simulations (patients demon-
strate a proposed technique, such as using an inhaler)
and direct observation. Throughout the intervention,
patients are asked to repeat key instructions and sum-
marise in their own words what they have learned and
understood. When patients do not achieve their goals
and objectives, the educational plan is revised and other
methods are used for education and building skills.
Follow-up session: The inclusion of a follow-up session as
part of the behaviour-change programme allows the
SCM to review with the participants their motivation to
continue to pursue their physical-activity goals. Barriers
and facilitators to continuing physical activity and possible
solutions are discussed. Finally, patients are thanked for
their participation and encouraged to continue to apply
the skills learned throughout the programme.
Individualised interventions: In order to respond to the
changing needs of individual patients with COPD as
they progress through the study, the behaviour-change
programme is designed to allow for adjustments. These
adjustments are based on feedback from the participants
to the SCM during the group sessions and analysis of
the results of the change-programme process-evaluation
tools completed by study participants at each interven-
tion visit. These measures are described below.
Behaviour-change process measures
An important note in terms of patient evaluation is the
difference between outcome measures and process mea-
sures (table 1).29–34 In clinical studies, outcome mea-
sures are used to test the effects of the intervention on
the patient; in this case, exercise capacity, the difficulty
and amount of daily activity, and other study end points
described above. The SCMs are blinded to the outcome
measures during the study. For behavioural interven-
tions, process measures are an important part of the
delivery of the intervention, permitting the therapist to
evaluate each participant’s progress and make adjust-
ments to the programme where needed. These measures
may also be useful during the interpretation of study
results (outcomes).
This behaviour-intervention programme includes a
series of questionnaires completed by patients during
the course of the intervention to assess the process of
change and permit the SCM to evaluate individual
patient needs and progress, and make adaptations to the
programme as needed over time. Questionnaires that
have been adapted for this study are completed during the
individual induction session with the SCM, and again at
weeks 5 and 11, and include the Physical Activity Outcome
Expectancies questionnaire, which assesses patients’ expec-
tations regarding outcomes of the study,30 the Perceived
Competence Scale (for physical activity), which assesses
patients’ confidence in their ability to engage in physical
activity,34 and the Treatment Self-Regulation Questionnaire
(for physical activity), which assesses different motivators
or reasons for engaging in physical activity.33 Three add-
itional questionnaires are administered by the SCM at all
sessions (figure 2). They include the stage of change (for
physical activity) visual analogue scale, which assesses readi-
ness to engage in physical activity,31 and two, 0–10
Table 1 Study outcome measures and process
measures*
Measure
Aspect being
measured/assessed
Study outcome measures
Endurance shuttle walk test Exercise capacity
6 min walk test29 Exercise capacity
Activity monitoring Physical activity
Functional Performance
Inventory—Short Form
Perceived ease or
difficulty with daily
activities
PROactive Amount and difficulty of
daily activity
Spirometry Lung function
Modified Borg Scale Intensity of breathing
discomfort
St George’s Respiratory
Questionnaire32
Health status
Heart rate, blood pressure,
oxygen saturation, adverse
events
Safety assessments
Montreal Cognitive
Assessment23
Cognitive function
Hospital Anxiety and
Depression Scale24
Anxiety and depression
Brief Patient Health
Questionnaire-mood25 26
Major depressive
disorder
Behaviour-change self-management programme process
measures
Physical Activity Outcome
Expectancies
questionnaire30
Patient expectancies of
physical activity
Perceived Competence
Scale34
Feelings of competence
about engaging in
healthier behaviour
Treatment Self-Regulation
Questionnaire33
Degree to which a
patient’s motivation for a
specific behaviour is
self-determined
Stage of change31 Readiness for change
Self-efficacy and motivation
questions related to specific
programme contents
Levels of motivation for
change and confidence
to change
*Outcome measures provide data on the effects of the
self-management intervention. Process measures inform the Site
Case Manager to help direct the self-management intervention.
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Likert-type scales assessing motivation (on a scale of ‘not at
all important’ to ‘very important’) and self-efficacy or con-
fidence (on a scale of ‘not at all confident’ to ‘very confi-
dent’) to engage in physical activity. To assess motivation,
we asked ‘How important do you think it is to maintain
regular physical activity, at least 30 min per day or x
number of steps?’. To assess confidence, we asked ‘How
confident are you in your ability to (1) use your pedometer
to track your progress, (2) maintain regular physical activ-
ity, at least 30 min per day or x number of steps?’. These
three additional questionnaires are completed to enable
the SCM to monitor patients’ motivation, confidence and
movement through the stages of change and to intervene
onsite if patients are not responding to the intervention in
the desired or expected direction.
The study coordinator at each study site receives the
original questionnaires and worksheets completed by
the SCM. These data are then entered into the remote
data-capture system; an overview of this process is shown
in figure 3.
Quality assurance
To ensure a standardised delivery of the behaviour-
change interventions, the programme is overseen by a
Global Behavioural Change (GBC) training team, which
provides 3 days of face-to-face training to SCMs. SCMs
receive a ‘reference guide’ describing the objectives,
interventions, suggested questions, expected results and
available resources for each intervention. SCMs also
review their own performance by completing self-
evaluation forms after each session. Additionally, record-
ings of the sessions are assessed by random sampling to
ensure all the educational topics have been covered
and that they are delivered by the SCM using the
behaviour-change strategies (eg, motivational communi-
cation skills) outlined in the protocol. Audio files are sent
for review by the SCM to the Country Case Manager
(CCM), who also acts as a country-specific cultural and
language liaison between the GBC team and SCMs. The
CCM completes a data-extraction form (see online
supplementary appendix 3), verifies that all educational
topics are covered and provides counts of the number of
times each motivational communication skill has been
used to deliver each topic. The CCM then provides con-
structive, corrective feedback to the SCM when necessary,
including positive feedback on good performance.
The GBC team reviews all the data-extraction forms
for quality assurance and provides feedback to the
CCM. This team will also lead eight additional web
conferences with CCMs to provide training support
and performance feedback for each site during the
conduct of the study. Feedback is provided to the SCM
via the CCM as required. Additional sessions may be
sampled to ensure quality is maintained. Reports are
produced by Local Clinical Monitors/Clinical Research
Associates or Clinical Quality Assurance Auditors and are
submitted to the global managers, who also provide
feedback to the SCM indirectly via the CCM. Finalised
reports are ultimately filed with the sponsor’s Study
Master File. Table 2 presents an overview of the study
design elements and quality-control process of the
behaviour intervention.
Further details relating to the design of the PHYSACTO
study are reported in our companion paper20 according
to the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) guidelines35 and a com-
pleted SPIRIT checklist is available online.
Ethics and data dissemination
The studies are to be carried out in accordance with the
principles of the Declaration of Helsinki and the
International Conference on Harmonisation Harmonised
Tripartite Guideline for Good Clinical Practice, and written
informed consent will be obtained from each patient.
DISCUSSION
This is the first multicentre study of maintenance
therapy in COPD in which all intervention arms
included a behaviour-change self-management pro-
gramme to facilitate increased physical activity during
daily life, with special attention to methodological issues
such as quality control. Particular focus is directed
towards the SCM, the patient (including patient
Figure 3 Data flow between SCMs and site coordinators. CCM, Country Case Manager; SCM, Site Case Manager.
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evaluation), and defining and implementing
quality-assurance activities. The incorporation of a
behaviour-change self-management programme in this
clinical trial aims to demonstrate that, with the use of
long-acting bronchodilators and behavioural self-
motivation interventions, there is potential to not only
influence exercise capacity but also improve the amount
and effort of physical-activity performance in patients
with COPD. Self-management programmes have been
proposed as the best way to assist patients in acquiring
and practising the necessary skills to control their
disease symptoms on a daily basis and to implement
healthy behaviours.36 37 The premise is that if patients
receive effective self-management support, they can be
empowered to adopt the behaviours needed to cope
optimally with their disease, so that many of the poor
outcomes related to chronic disease can be averted.
However, studies have not been consistent in demon-
strating benefits. From a recent literature review,17 sig-
nificant improvements in physical activity in patients
with COPD were shown in five out of eight evaluable
studies. The five successful studies were based on theoret-
ical models of behaviour change and included exercise
interventions of approximately 30 min, 3–5 times a week.
Behavioural interventions ranged from counselling and
personal contact to educational pamphlets.17 This study
builds on this insight by including and documenting a
comprehensive, well-defined behavioural self-
management intervention programme designed specific-
ally to effect change in patients’ physical activity.
The effectiveness of any complex intervention, such
as self-management in patients with COPD, crucially
depends on the healthcare professionals and the delivery
of the intervention to the patient. Most studies published
to date give little attention to personnel and processes. In
our study, SCMs are required to have recognised expertise
in COPD and at least 2 years’ experience in order to par-
ticipate. In addition, SCMs are provided with 3 days’ train-
ing based on the self-management educational programme
‘Living Well with COPD’. SCMs are also supported through
educational opportunities and feedback during the study
by the CCMs and the GBC team.
There is still no accepted best practice for the level of
qualification and training required for the SCM, and no
evidence that training is effective. However, it is gener-
ally accepted that training in behaviour-change and self-
management skills is needed. SCMs are likely to benefit
from having at least basic training in the principles of
behaviour change, as well as basic training in motivational
communication skills, including methods to engage,
motivate and build confidence in patients. However, one
of the most important challenges to overcome is the gap
between how the intervention is designed to be delivered
and how the SCM actually delivers it. This gap is clearly
underestimated or underevaluated in most behavioural
studies, as well as in practice. Furthermore, being able to
assess and provide feedback to the SCM is necessary to
ensure best practice.
In our study, we planned and implemented several
quality-assurance assessments to reduce the potential of
failing to deliver the intervention in the way it was
intended. All sessions between patients and SCMs are
audio-recorded and randomly assessed for quality assess-
ment and feedback, the programme delivery is assessed
in a standardised way (including careful monitoring and
recording of the use of motivational communication
skills with patients) and feedback on SCM performance
is provided and followed up to assess the effectiveness of
any corrective steps. Evaluating whether the SCM inter-
vention is delivered as intended is the most important
part of quality assurance, and a crucial and novel meth-
odological consideration in this study.38
The international, multisite design of this study is a
significant challenge. Audio files of SCMs’ performances
have to be reviewed using a standardised data-extraction
sheet by a CCM who acts as a country-specific cultural
and language liaison. Finally, we have in place a GBC
team that reviews all the data-extraction forms and pro-
vides systematic and timely feedback to the CCM.
Another very important methodological aspect of this
study is the attention we give to relevant ‘enablers’ for
behaviour modification in attempting to effect change
in patients’ levels of physical activity, while acknowledg-
ing that physical activity is itself a behaviour. It is well
recognised that it is important to equip patients with the
proper techniques and skills (eg, knowledge and confi-
dence) required to effectively self-manage their condi-
tion. Furthermore, enhancing patients’ motivation to
change and overcome ambivalence is crucial. This is
best achieved using patient-centred, motivational com-
munication techniques that encourage participants to
Table 2 Study design elements from PHYSACTO for the
standardisation and sustainability of the behaviour-change
intervention
Level Action
SCM and
patient
Audio-record sessions
Clearly label tapes and provide to the site
coordinator
Site
coordinator
Review identification and control log
Carry out session sampling (two random
induction sessions per cohort, two
random group sessions and two random
follow-up sessions)
Send to the CCM
Destroy records
CCM Assess tapes
Complete data-extraction forms and send
to the GBC team
Provide immediate feedback to the SCM
as needed
GBC team Review data extractions
Provide feedback to the CCM
CCM, Country Case Manager; GBC, Global Behaviour Change;
SCM, Site Case Manager.
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express their intrinsic motivations to adopt certain
health behaviours (eg, consistent with their values or life
goals). Questionnaires to assess the process of change
have been adapted for this study and are completed by
the patient (with the SCM) at multiple time points to
evaluate progress. These questionnaires assess motiv-
ation, perceived competency (confidence), readiness to
change and expectancies of physical activity. The main
purpose of these process measures is to inform the SCM
of a patient’s progress and to help direct and individual-
ise the self-management intervention.
The results of these questionnaires inform the perso-
nalised delivery of the behavioural intervention to
patients based on their readiness to change and progress
in the programme. To date, most studies have limited
assessments to trial outcome measures. By including
process measures, the intent is to not only intervene
more effectively during the course of the intervention
but also gather information that could facilitate the
interpretation of study outcomes.
To date, most published randomised clinical studies with
behaviour interventions have not described the specific
components of the intervention, nor have they included
or described process measures to track changes in
patients’ behaviour and make individualised adjustments
to enhance the effects of this therapy. As such, evidence of
established processes and procedures for the implementa-
tion and monitoring of behavioural studies is lacking.
Being able to better define and implement such a pro-
gramme, and making it accessible in practice, would be
highly valuable. However, this can only be accomplished
by raising the standards and quality of evidence-based
behaviour interventions and programmes. This multicen-
tre study is a first step towards integrating a more coherent
and careful plan at the patient, provider (health profes-
sional/case manager) and system or organisational levels.
CONCLUSIONS
This is the first study to use a multifactorial intervention to
improve exercise capacity and physical activity in patients
with COPD, incorporating pharmacotherapy, exercise
training and behaviour change. This paper documents the
comprehensive methods being used to optimise and stand-
ardise the behaviour-change self-management programme
used in the study to facilitate dialogue on the inclusion of
this type of programme in multicentre studies.
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